RECENT SMALL MOLECULES WITH BIFUNCTIONAL HDAC THERAPEUTICS

 Jemi Jacob*, Neethu Varghese, Nija B, Shebina P Rasheed, Aishwarya PJ and Muhammed Jamshad

ABSTRACT

Histone deacetylases (HDACs) are studied as prime targets for a broad radius of neoplasm and other diseases, they are associated with the initiation, expansion and viability of tumor cells. However, the built-in diverseness and numerous genetic deformity of various diseases question the clinical utilization of these single target focussed drugs. To control the problems associated with single target perspective, a way out approach is to target HDACs and other relevant targets of the disease at the same time like Topoisomerase, Cyclin-dependent kinase, Heat shock protein, Janus kinase, VEGF, CYP51, EGFR, LSD1, BRD4, etc. with a single drug attracted a great deal of attention of in drug discovery and development process. New molecules were synthesized which incorporate the binding characteristics of both the targets. This review highlights the recent discovery and development of small molecules synthesized as dual inhibitors against HDACs and other related protein targets for the disease. Considerable studies were undertaken to discover molecule having duel HDAC inhibitory potential and thereby, various drugs have emerged from this attempt.

Keywords: HDAC, duel inhibitors, Cell lines, structures, Topoisomerase.